Lung cancer is the leading cause of cancer deaths in the world today.1

The standard of care for lung cancer has been a combination of surgery, chemotherapy, and radiation. But each of these therapies is fraught with significant collateral damage.

Precision oncology seeks to minimize the adverse side effects associated with surgery, chemotherapy, and radiation by offering a more targeted approach.

Listen to why we believe Precision Oncology is a compelling investment theme as Eventide CIO Finny Kuruvilla, MD, PhD, explains how treating cancers like lung cancer at the molecular level yields fewer side effects and better outcomes.
Author

Finny Kuruvilla, MD, PhD

Co-Chief Investment Officer, Senior Portfolio Manager, Managing Director, Founding Member

Finny Kuruvilla, MD, PhD, serves as a Co-Chief Investment Officer, Senior Portfolio Manager for Eventide’s strategic growth strategies and healthcare & life sciences strategies, a Managing Director for Eventide Ventures, as well as Founding Member of Eventide. 

Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital. 

Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech. 

References
1“Cancer.” World Health Organization. Accessed May 27, 2020. https://www.who.int/news     -room/fact-sheets/detail/cancer.